Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

Immediate-release (IR) formulation of linaclotide 290 μg improves abdominal pain and constipation (APC) in patients with irritable bowel syndrome (IBS) with constipation. Delayed-release (DR) formulations were developed on the premise that targeting the ileum (delayed-release formulation 1 [DR1]) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Chey, William D., Sayuk, Gregory S., Bartolini, Wilmin, Reasner, David S., Fox, Susan M., Bochenek, Wieslaw, Boinpally, Ramesh, Shea, Elizabeth, Tripp, Kenneth, Borgstein, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279899/
https://www.ncbi.nlm.nih.gov/pubmed/33065589
http://dx.doi.org/10.14309/ajg.0000000000000967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279899/
https://www.ncbi.nlm.nih.gov/pubmed/33065589
http://dx.doi.org/10.14309/ajg.0000000000000967

Ejemplares similares